Cargando…
Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron
OBJECTIVE: The objective of this study was to characterize the impact of casopitant, a novel neurokinin-1 receptor antagonist under investigation for the prevention of postoperative and chemotherapy-induced nausea and vomiting, on the pharmacokinetics of the commonly prescribed 5-hydroxytryptamine r...
Autores principales: | Adams, Laurel M., Johnson, Brendan, Zhang, Ke, Yue, Lin, Kirby, Lyndon C., Lebowitz, Peter, Stoltz, Randall |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726911/ https://www.ncbi.nlm.nih.gov/pubmed/19205754 http://dx.doi.org/10.1007/s00520-008-0572-4 |
Ejemplares similares
-
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone
por: Johnson, Brendan, et al.
Publicado: (2009) -
Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting
por: Ruhlmann, Christina, et al.
Publicado: (2009) -
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Schwartzberg, Lee, et al.
Publicado: (2013) -
Reappraisal of the role of dolasetron in prevention and treatment of
nausea and vomiting associated with surgery or chemotherapy
por: Roberts, S Michael, et al.
Publicado: (2012) -
Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy [Erratum]
Publicado: (2016)